MedTrace Logo

BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach

NCT02758288 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-10-05

No results posted yet for this study

Summary

The investigator's aim in this study is to evaluate the impact of a new standard of care protocol for the treatment of BK viremia and nephropathy (BKVAN), which includes switching from Tacrolimus to equivalent dose of Cyclosporine in patients who have been diagnosed with BK viremia or BKVAN based on their viral load, overall graft function (estimated glomerular filtration rate), acute rejection, and rate of graft loss due to rejection or BKVAN.

Conditions

  • BK Virus Infection
  • BK Virus Nephropathy

Interventions

OTHER

New Protocol - BK viremia or BK virus nephropathy

Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.

OTHER

Standard Protocol - BK viremia or BK virus nephropathy

Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Amir Abdipour, MD · Loma Linda University Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-07-31
Completion
2022-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02758288 on ClinicalTrials.gov